Search

Your search keyword '"Peter G. Mortimer"' showing total 4 results
Start Over Author "Peter G. Mortimer" Publisher elsevier bv
4 results on '"Peter G. Mortimer"'

1. OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

Author

Peter G. Mortimer, Emma Dean, J. Cosaert, Maximilian Hochmair, Benjamin Besse, C. Hayward, Z. Szucs, F. Huemer, Kwang Bo Park, Naiyer A. Rizvi, Patrick M. Forde, John V. Heymach, M. Dressman, Helen Ambrose, Michael Thomas, Glenwood D. Goss, S. Barry, Jaafar Bennouna, Mark M. Awad, R. Hobson, and Kris Sachsenmeier

Subjects
Pulmonary and Respiratory Medicine, Oncology, Drug, medicine.medical_specialty, business.industry, media_common.quotation_subject, Internal medicine, medicine, Biomarker (medicine), In patient, Open label, business, media_common
Published
2021

2. P16.07 Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON)

Author

M. Hernandez, Patrick M. Forde, John V. Heymach, Carl Barrett, A. Coenen-Stass, Naiyer A. Rizvi, M. Dressman, Mark M. Awad, Kris Sachsenmeier, C. Hayward, Glenwood D. Goss, Benjamin Besse, R. Hobson, J. Cosaert, Kwang Bo Park, Michael Thomas, Helen Ambrose, Emma Dean, Z. Szucs, and Peter G. Mortimer

Subjects
Pulmonary and Respiratory Medicine, Durvalumab, Oncology, business.industry, Cancer research, Medicine, business
Published
2021

3. AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Author

Natalie Cook, J.S. de Bono, Mark Linch, Wolfram Brugger, Peter G. Mortimer, Elisabeth I. Heath, E. De Bruin, Kari B. Wisinski, Simon T. Barry, Aaron R. Hansen, Teresa Klinowska, Juan Martin-Liberal, L.L. Siu, Celestia S. Higano, Ananya Choudhury, Dana E. Rathkopf, Michele Moschetta, Geoffrey I. Shapiro, and S. Colebrook

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, Abiraterone acetate, Castrate-resistant prostate cancer, Urology, Hematology, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, Oncology, chemistry, Prednisone, 030220 oncology & carcinogenesis, medicine, In patient, business, medicine.drug
Published
2018

4. P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)

Author

Philip J. Jewsbury, Wolfram Brugger, Patrick M. Forde, Sabina Patel, Helen Ambrose, Kwang Bo Park, Peter G. Mortimer, Naiyer A. Rizvi, John V. Heymach, Michael Thomas, Si-Houy Lao-Sirieix, Glenwood D. Goss, B. Koetz, Mark M. Awad, Benjamin Besse, and Kris Sachsenmeier

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Biomarker (medicine), Medicine, Open label, business
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results